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osting by EAbstract Two highly sensitive and simple spectrophotometric methods were developed to quanti-
tate the drug cyclizine (CYC) in its pure form and in a pharmaceutical formulation. The twomethods
involved ion-associate formation reactions (method A) with mono-acid azo dyes, i.e., sudan (I) and
sudan (II), as well as ion-pair reactions (method B) with bi-azo dyes, i.e., sudan (III), sudan (IV) and
sudan red 7B (V). The reactions were extracted with chloroform, and the extraction products were
quantitatively measured at 480, 550, 500, 530 and 570 nm using reagents I–V, respectively. The reac-
tion conditions were monitored and optimised. The Beer plots for reagents I–V showed linear rela-
tionships for the concentrations of 4.2–52.0, 5.4–96.0, 3.5–43.0, 4.4–80.0 and 0.6–18.0 lg mL1,
respectively, with molar absorptivities of 2.2 · 104, 4.1 · 104, 3.6 · 104, 2.5 · 104 and 1.3 ·
104 L mol1 cm1, respectively. Sandell sensitivities and detection limits were calculated and ana-
lysed. The implementation of the two methods to the analysis of a commercial tablet (Valoid) suc-
ceeded, and the recovery study suggested that there was no interference from common excipients in
the tablet. Regarding the accuracy and precision of the methods, a statistical comparison of the
results was performed using Student’s t-test and the F-test at the 95% conﬁdence level. The accuracy
and precision of the proposed methods were not signiﬁcantly different.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.503167512.
com
y. Production and hosting by
Saud University.
lsevier1. Introduction
Cyclizine (CYC) (Scheme 1), 1-(diphenylmethyl)-4-methylpi-
perazine or 1-benzhydryl-4-methylpiperazine (Benezra, 1977),
is a piperazine derivative that has been used effectively for
the prevention and treatment of nausea and vomiting associ-
ated with motion sickness (Chinn et al., 1952; Dundee and
Jones, 1968). The synthesis of cyclizine was reported by Baltzly
et al. (1949). Its anti-histaminic action was discovered by
Castillo et al. (1949), and it was reported to be 1/4 as active
as its congener, chlorcyclizine, in blocking the histamine-
induced spasm of the tracheal chain preparation. The use of
cyclizine hydrochloride for the prevention of seasickness and
Scheme 1 Cyclizine.
256 N.H. Al-Shaalanairsickness has been described by Chinn et al. (1952, 1953).
Gutner et al. (1954) published methods for the quantitation
of cyclizine in dosage forms, including colorimetry (Sane and
Vaidya, 1979), potentiometry (Campbell and Demetriou,
1980), second derivative UV spectrophotometry (Davidson
and Hassan, 1984; El-Gindy et al., 2004), LC–MS/MS (Jensen
et al., 2011, HPLC (Low et al., 1983; Jalal et al., 1988; Jonczyk,
1999) and capillary zone electrophoresis (Mohammadi et al.,
2004). Azo dyes are of interest because of their chromophoric
nature and the bidentate character of their ortho-phenolic hy-
droxyl groups. These properties have made azo dyes useful for
metal complexation studies (Kupleskaya et al., 1988) and for
spectroscopic measurements of cation concentrations (Barek
et al., 1982).
Chromatographic methods for the determination of cycli-
zine concentrations require an automated system not available
in many research laboratories. Therefore, it was considered
worthwhile to develop rapid and sensitive methods suitable
for the routine quality control analysis of the investigated
drug. Spectrophotometry is still the most frequently used ana-
lytical technique for pharmaceutical analysis, providing practi-
cal and signiﬁcant economic advantages compared to other
methods. Therefore, I investigated new spectrophotometric
methods for the quantitation of cyclizine in its pure form
and in pharmaceutical formulations. This method is based
on the formation of ion-associate and ion-pair complexes with
mono- and bi-acid azo dyes.
2. Materials and methods
2.1. Materials
Cyclizine was purchased from Sigma–Aldrich (St. Louis, MO,
USA). Valoid (Amdipharm, UK) tablets contained 50 mg of
cyclizine hydrochloride. Double-distilled water was used
throughout the study. Sudan (I), sudan (II), sudan (III), sudan
(IV) and sudan red 7B (V) were obtained from Sigma–Aldrich.
The structures of these dyes are shown in Scheme 2.
2.2. Equipment
Absorption spectra were measured using a Shimadzu UV-1601
(UV–visible) spectrophotometer equipped with a 10 mmScheme 2 Sudan (I).matched quartz cell and operated with a scanning rate of
200 nm min1 and a bandwidth of 2.0 nm.
2.3. Stocks solutions and standards
Stock solutions (3 · 103 M) of azo dyes were prepared by dis-
solving an accurately weighed amount of pure solid in 50 mL
of ethanol. These solutions were stable for several months.
A standard stock solution of cyclizine (1 mg mL1) was
prepared in water. The solution was protected from light using
aluminium foil and stored at 4 C. The prepared drug solution
was stable for 5 days at ambient temperature.
2.4. General procedures for the quantitation of CYC
2.4.1. Method A (mono-azo dyes)
A volume equivalent to 2 mg of CYC was transferred to a
50 mL separatory funnel. Two millilitre of 0.5 N HCl and
1.5 mL of 3 · 103 M I or 3 mL of 3 · 103 M II were added,
and double-distilled water was added to a ﬁnal volume of
10 mL. The produced ion-associates were extracted by shaking
for 5 min with 5 mL of chloroform. The extraction process was
performed three times using three separate additions (5 mL
each) of chloroform. Each time, the mixture was left to sepa-
rate into two phases. The four extracts were combined in a
25 mL volumetric ﬂask, and the absorbance at 480 nm (for I)
or 550 nm (for II) was measured against a blank sample pre-
pared in the same way. All the measurements were performed
at room temperature (25 ± 1 C) (Scheme 3).
2.4.2. Method B (bi-azo dyes)
A volume equivalent to 3 mg of CYC was transferred into a
50 mL separatory funnel. Two millilitre of 0.5 N HCl and 2,
2 and 3 mL of 3 · 103 M III, IV and V, respectively, were
added, and double-distilled water was then added to a ﬁnal
volume of 10 mL. The produced ion-pairs were extracted by
shaking for 5 min with 5 mL of chloroform. The extraction
process was repeated with another 10 mL aliquot of chloro-
form. The mixture was left to separate into two phases. The
two extracts were combined in a 25 mL calibrated measuring
ﬂask, and the absorbance at 500 nm (III), 530 nm (IV) or
570 nm (V) was measured against a blank sample prepared
in the same way. All the measurements were performed at
room temperature (25 ± 1 C) (Scheme 4).
2.5. Procedure for the pharmaceutical preparation
Five tablets (Valoid, 50 mg/tablet) were weighed and ground
into a powder. Powder corresponding to 50 mg of the drug
was weighed and dissolved in 0.1 N HCl and then transferred
to a 50 mL volumetric ﬂask to make a solution of 1000 g mL1.
Using the same acid, the solution was diluted to a ﬁnal volume
of 50 mL, mixed, ﬁltered and then analysed according to meth-
od A or B.Scheme 3 Sudan (II).
Scheme 4 Sudan (III). Scheme 6 Sudan red 7B (V).
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The appropriate amounts of standard solutions of CYC were
added to 1 mL of plasma sample. One millilitre of 10% (w/v)
trichloro-acetic acid was added for each mL of the plasma for
deproteination. The sample was centrifuged at 3500 rpm for
10 min. Two millilitres of protein-free supernatant was trans-
ferred into 10 mL volumetric ﬂask and the above procedure
was then followed (Walash et al., 2003).
2.7. Procedure for spiked human urine samples
Ten millilitres of CYC free urine taken in a 125 mL separating
funnel was spiked with 10 mL of aqueous solution containing
2.5 mg of pure CYC and to the same solution, 5 mL of carbon-
ate–bicarbonate buffer of pH 9.5 was added followed by
20 mL of ethylacetate, shaken well for about 15 min and the
upper organic layer was collected in a beaker containing anhy-
drous sodium sulphate. The water-free organic layer was trans-
ferred into a dry beaker and solvent removed by evaporation
on a hot water bath. The dry residue was dissolved in glacial
acetic acid and transferred into a 25 mL calibrated ﬂask, and
diluted to the mark with the same acid. An aliquot of resulting
solution was analysed following the procedures described
above.
2.8. Stoichiometric study
The Job method for continuous variation was employed to
determine the stoichiometric ratios (Job, 1928). Methods A
and B were applied with different volumes of 1 · 103 M
CYC (ranging from 0.5 to 4.2 mL), and CYC was treated by
the addition of 1 · 103 M I, II, III, IV or V to give a total vol-
ume of 4 mL (Scheme 5).
2.9. Determination of the stability constants of the ion-associates
and ion-pairs
The detailed examination of the ion-pairs (1:1) was performed
using the Benesi–Hildebrand method (Benesi and Hildebrand,
1949). This method involved the mixing of different concentra-
tions of the drug solution (1.5 · 104 to 3 · 103 M) with 2 mL
of 0.5 N HCl and 2, 2 and 3 mL of 3 · 103 M III, IV and V,
respectively. The examination was performed according to
method B. The stability constant of the ion-pairs and theScheme 5 Sudan (IV).ion-associates (Kf) was determined by substituting the data ob-
tained from the continuous variation in an equation derived
for calculating the stability constant spectrophotometrically
(Inczedy, 1976) (Scheme 6).
Kf ¼ ðA=AmÞ½1 A=Amnþ1Cnnn ð1Þ
where A is the maximum absorbance obtained from the Job
continuous variation curve, Am is the absorbance correspond-
ing to the intersection between the two tangents of the contin-
uous variation curve, C is the concentration corresponding to
the maximum absorbance, and n is the drug ratio in the reac-
tion product.
3. Results and discussion
Nitrogenous drugs are predominantly positively charged in
slightly acidic solutions. Electronic resonance and steric effects
make the protonation process disfavoured in substituted and
fused diphenyl ring systems. Therefore, the expected proton-
ation site of CYC is the nitrogen atom bonded to the elec-
tron-donating methyl group of the piperazine ring. The
positively charged CYC ion interacts with anionic dyes such
as azo dyes to form ion-pairs or ion-associates that can be ex-
tracted by organic solvents. To obtain higher sensitivity and
reproducibility, an initial study was conducted to determine
the optimal conditions for colour development.
3.1. Effect of the acidity
The presence of an acidic medium is essential for obtaining the
electrophilic form of CYC. Therefore, different types of acids,
including acetic, hydrochloric, nitric and sulphuric acids, were
tested (each at a concentration of 0.5 N). High absorbance
readings with the blank sample, non-reproducible results or
low sensitivities were observed for all the acidic media except
for hydrochloric acid (which provided the best result). Optimi-
sation studies showed that 2 mL of 0.5 N HCl was sufﬁcient to
yield high and stable absorbance values. In addition, acidic
buffer solutions (pH 0.2–2.2) resulted in less precise readings
compared to hydrochloric acid solutions. The effect of the
pH on the absorbance of CYC ion-pairs and ion-associates
was studied in a separate series of experiments. The results
showed an increased absorbance for pH 0.2–0.3 because of
the increased electrophilicity of the CYC ion. The maximum
absorbance was observed at pH 0.3–1.5; the absorbance de-
creased at pH > 1.50 (Fig. 1) because the formation of the
electrophilic form of the drug was difﬁcult at pH > 1.50.
3.2. Effect of the reagent concentration
The inﬂuence of the reagent concentration was studied for sev-
eral volumes (1–5 mL) of a 3 · 103 M solution of each reagent
(I–V) with a ﬁxed concentration of the drug. The results
Figure 1 Effect of the pH on the absorbance of CYC complexes
with reagent I–V.
Figure 2 Job’s method of CYC complexes with reagent I–V.
258 N.H. Al-Shaalanrevealed that 1.5, 3, 2, 2 and 3 mL of I, II, III, IV and V, respec-
tively, were sufﬁcient to generate the maximum, reproducible
colour intensity in a series of drug, acid and reagent
applications.
3.3. Effects of the temperature and the reaction time
The aqueous reaction was performed at different temperatures
(10–90 C). The results showed an increased absorbance within
a certain temperature range (10–20 C). In contrast, the absor-
bance did not change at higher temperatures (20–60 C). The
absorbance decreased at higher temperatures likely because
of the dissociation of ion-pairs or ion-associates. The effect
of the reaction time on the formation of product was evaluated
at 25 ± 1 C by allowing the reaction to progress for different
times. The reaction was complete within a 5 min, and longer
reaction times did not affect the absorbance. The effect of time
on the stability of the ion-associates and ion-pairs was exam-
ined by monitoring the absorbance of the extract at different
times. The absorbance was stable for 24 h, which enhanced
the reliability of the methods and rendered them applicable
for the processing of a large number of samples.
3.4. Effect of the extraction solvent
No colour change was observed when water was used to dilute
the reaction mixture. This suggests that the reaction is incom-
plete in the aqueous medium. Therefore, water could not be
used as a solvent for the immediate absorbance measurements.
Several water-miscible and water-immiscible solvents were
tested to ﬁnd the most convenient organic solvent for the reac-
tion. Water-miscible solvents such as methanol, ethanol and
isopropanol resulted in low intensities compared with
water-immiscible solvents such as benzene, toluene, carbon tet-
rachloride, chloroform, methylene chloride, 1,2-dichloroeth-
ane and diethyl ether. The results showed that extractions
with chloroform provided the highest intensities for all of the
dyes. Ratios of 2:1 and 1:1 (aqueous/organic solvent) were
the most appropriate for the extraction of ion-associates and
ion-pairs of mono-azo (I and II) and bi-azo (III, IV and V)
dyes, respectively. The reaction was completely extracted by
four consecutive extractions (each with 5 mL of chloroform)
for reagents I and II or two consecutive extractions (each with
10 mL of chloroform) for reagents III, IV and V.3.5. Stoichiometry of the ion-associates
The Job method was applied to determine the stoichiometry of
the reaction between CYC and the azo dyes under optimal
conditions (Job, 1928). As shown in Fig. 2, the Job plot was
bell-shaped, indicating that the CYC:reagent ratio was 1:2
and 1:1 for the mono-azo (I and II) and bi-azo (III, IV and
V) dyes, respectively.
3.6. Association constant and the free energy
The Benesi–Hildebrand method was employed for determining
the association constant of 1:1 complexes by applying the fol-
lowing equation:
½Ao=AADk ¼ 1=eAD þ ð1=KADc :eADk Þ:1=½Do ð2Þ
where ½Do and ½Ao are the total concentrations of the drug
and the reagent, respectively AADk and e
AD are the absorbance
and the molar absorptivity of the complex at 500, 530 and
570 nm for reagents III, IV and V, respectively, and KADc is
the association constant of the complex. Fig. 3 shows the
straight line acquired by plotting the values of ½Ao=AAD versus
1=Do; the slope of this line equals 1=K
AD
c :e
AD and the intercept
are equal to 1=eAD. However, the molar absorptivity of the
complex itself ðeADÞ should not be confused with any stoichio-
metrically calculated values according to the amount of any
analyte being determined, which is best described as the Beer
value, while the molar absorptivity of the complex is the Bene-
si–Hildebrand value. Table 1 lists the molar absorptivities eAD
and the association constants K. Using Eq. (1) and the contin-
uous variation data listed in Table 1, the stability constants
(Kf) of the CYC complexes with reagents I–V were calculated
(Inczedy, 1976). The following equation shows the relation be-
tween DG (the standard free energy of complexation) and the
association (or formation) constant K (Martin et al., 1983):
DG
 ¼ 2:303 RT logK ð3Þ
where DG is the free energy change of the complex, R is the
gas constant (1.987 cal mol1 degree1), T is the temperature
in Kelvin, and K is the association (or formation) constant
(L mol1) of the drug-reagent complex. The negative values
of the calculated free energies imply that the complexes are sta-
ble and form spontaneously.
Figure 3 Benesi–Hildebrand plots for CYC ion-pair with bi-azo
dyes (III–V).
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Standard calibration curves for CYC were determined under
the optimised conditions (i.e., acidity, reagent concentration
and extraction solvent) using the different reagents. For each
reagent, the molar absorptivities, Sandell sensitivities, regres-
sion equations and correlation coefﬁcients were calculated.
The least square method was used to derive the regression
equations for the suggested procedures, and the values of the
correlation coefﬁcient ranged from 0.9991 to 0.9999. To vali-
date the analytical procedures, both the detection limit (DL)
and the quantiﬁcation limit (QL) were determined (Miller
and Miller, 1993). The parameters of the proposed methods
are summarised in Table 1.
3.8. Reproducibility
To determine the reproducibility of the methods, three sepa-
rate solutions of the working standard were analysed atTable 1 Analytical parameters for determination of cyclizine hydro
Parameters Reagents
I II
kmax (nm) 480 55
Beer’s law (lg mL1) 4.2–52.0 5.
Molar absorptivity (L mol1 cm1) 2.2 · 104 4.
Sandell sensitivity (lg mL1) 4.8 · 102 5.
Limit of detection (LOD) (lg mL1) 0.81 0.
Limit of quantiﬁcation (LOQ) (lg mL1) 2.43 2.
Slop (a) (mL lg1 mL1) 1.7 · 102 1.
Intercept (b) 5.0 · 103 3.
Correlation coeﬃcient (r) 0.9991 0.
R.S.D. % 1.5 1.
KADc (L mol
1) – –
eAD (L mol1) – –
DG (kcal mol1) – –
Kf (L mol
1) 2.8 · 105 7.
DG (kcal mol1) 10.12 
R.S.D. % is the relative standard deviation of ﬁve determinations. KADc
method. Kf is the formation constants calculated from the continuous vadifferent concentrations. The relative standard deviations
(R.S.D. %) were 0.3–1.62%, suggesting that the proposed
methods were reproducible (Table 2). This precision level is
appropriate for the precise, routine analysis of drugs in quality
control laboratories. To demonstrate the validity and applica-
bility of the suggested methods, the experiments were repeated
four times per day on three different days with one concentra-
tion of CYC. The methods are highly reproducible (Table 3)
because the R.S.D is lower than 2.0% within the same day
and lower than 1.3% between days.
3.9. Selectivity
The recovery of CYC was evaluated to determine the selectiv-
ity of the described methods. The recovery values ranged from
99.60 ± 0.54% to 100.26 ± 0.84% (Table 2), indicating the
accuracy of the described method. Before the analysis of the
CYC dosage forms, the interference requirements were estab-
lished to determine the inﬂuence of common excipients that
might be included during formulation. The sample preparation
involved the mixing of a known amount of CYC (0.52 mg of
CYC for reagents I and II and 0.95 mg of CYC for reagents
III, IV and 0.31 in case of reagent V) with 2 mL of a 1% solu-
tion of fructose, maltose, glucose, sucrose, urea or starch. The
proposed method was then applied to analyse samples that had
been prepared using generally recommended procedures. The
recoveries ranged from 99.1% to 101.01%, and the average
recovery was 100%. These data conﬁrmed that the quantiﬁca-
tion of CYC by the proposed methods is free of interference
from any of the common excipients.
3.10. Applications
The suggested methods clearly afforded satisfying results for
CYC in a pure solution. Thus, the suggested methods and a
previously reported method (El-Gindy et al., 2004) (based on
the direct measurement of the absorbance of the formed
charge-transfer complex) were used to determine the CYCchloride using some azo dyes.
III IV V
0 500 530 570
4–96.0 3.5–43.0 4.4–80.0 0.6–18.0
1 · 104 3.6 · 104 2.5 · 104 1.3 · 104
1 · 102 6.4 · 102 7.3 · 102 2.4 · 102
93 1.07 1.19 0.4
87 3.12 3.37 1.03
6 · 102 1.9 · 103 2.4 · 102 1.4 · 102
5 · 103 7.6 · 103 3.3 · 103 4.5 · 103
9993 0.9999 0.9997 0.9998
3 1.6 2.1 1.4
3.87 · 103 2.15 · 103 1.94 · 103
5.87 · 103 4.92 · 103 3.68 · 103
3.91 4.12 4.36
1 · 106 3.4 · 105 6.4 · 107 2.4 · 105
9.54 11.08 8.87 7.91
is the association constants calculated applying Benesi–Hildebrand
riation data.
Table 2 Evaluation of precision of the proposed methods on cyclizine hydrochloride pure and pharmaceutical formulations (Valoid
tablets).
Reagent Proposed methods Recovery %± S.D. R.S.D. % t-testa F-testa Reference methodb
Taken lg Found lg Recovery %± S.D.
Pure forms I 20 20.05 100.25 ± 0.54 1.25 1.60 1.94 100.32 ± 2.45
40 39.98 99.95 ± 0.68 1.08 0.25 4.31 100.16 ± 3.48
80 80.01 100.01 ± 0.91 1.20 1.13 2.03 99.98 ± 4.61
II 20 19.99 99.95 ± 0.34 1.70 1.90 2.54
40 40.00 100.00 ± 0.91 1.30 2.61 2.35
80 80.01 100.01 ± 0.64 0.92 0.19 3.45
III 15 15.04 100.26 ± 0.84 0.79 2.10 5.14 100.19 ± 0.54
30 30.07 100.23 ± 0.51 0.76 0.42 4.36
60 59.94 99.90 ± 0.52 1.10 1.28 4.35
IV 25 24.96 99.84 ± 0.57 1.26 1.18 3.65
50 49.93 99.86 ± 0.25 1.40 0.32 2.84
100 100.01 100.01 ± 0.94 0.90 1.59 2.46
V 20 20.00 100.00 ± 0.75 1.00 1.12 4.12 100.49 ± 1.34
40 40.01 100.02 ± 0.46 1.21 1.11 3.84
80 80.07 100.08 ± 0.85 1.62 0.10 2.46
Valoid tablets I 20 19.92 99.60 ± 0.54 2.50 0.41 2.81 100.03 ± 3.22
40 39.98 99.95 ± 0.95 0.95 2.20 1.94 100.06 ± 1.36
80 79.94 99.93 ± 0.58 0.73 1.77 100.87 ± 2.13
II 20 20.00 100.00 ± 0.68 1.04 0.22 4.67
40 40.02 100.05 ± 0.78 0.65 1.87 3.86
80 80.04 100.05 ± 0.25 1.06 1.19 4.01
III 15 14.97 99.80 ± 0.65 1.10 0.25 1.64 99.97 ± 2.31
30 29.97 99.90 ± 0.95 1.05 0.24 1.98
60 60.04 100.06 ± 0.68 1.01 0.32 1.75
IV 25 25.03 100.12 ± 0.18 1.30 0.59 2.01
50 50.09 100.18 ± 0.58 0.95 1.87 1.96
100 99.98 99.98 ± 0.57 0.94 0.39 1.88
V 20 20.00 100.00 ± 0.25 1.05 1.27 3.49 100.54 ± 1.34
40 40.05 100.12 ± 0.58 1.65 0.7 4.65
80 79.99 99.99 ± 0.48 1.98 0.36 3.56
R.S.D. % is the relative standard deviation of ﬁve replicate analysis.
a Theoretical value for t- and F-test are 2.776 and 6.39, respectively, for four degree of freedom and 95% conﬁdence limit.
b El-Gindy et al. (2004).
Table 3 Inter-day and intra-day precision of cyclizine hydrochloride in pure form using the cited reagents.
Reagent Taken lg Inter-day precision Intra-day precision
Recoverya %± S.D. R.S.D. % Recoveryb %± S.D. R.S.D. %
I 25 100.02 ± 0.34 1.36 99.37 ± 0.19 1.72
II 25 99.98 ± 0.76 1.32 99.46 ± 0.45 2.09
III 50 99.85 ± 0.75 0.93 99.96 ± 0.46 1.48
IV 50 99.79 ± 0.84 1.24 99.75 ± 0.54 1.35
V 15 100.17 ± 0.58 1.03 99.78 ± 0.67 1.28
a Average value of four determinations.
b Average value of three determinations.
260 N.H. Al-Shaalancontent of a pharmaceutical preparation (Valoid tablets). The
recovery percentages using the proposed methods ranged from
99.60 ± 0.54% to 100.12 ± 0.18% (Table 2). Furthermore, to
validate the proposed methods, CYC was added to the Valoid
solution using the standard addition method. The recovery of
the dosage form and the pure form of CYC was calculated by
comparing the concentration determined for the spiked mix-
ture with that determined for the pure form. Table 4 lists the
calculated recoveries (using the standard addition method)
and the analysis of the pharmaceutical dosage form. These re-
sults suggested that the excipients that are present in the tabletdo not interfere with the quantitation of CYC. Tables 2 and 4
compare the results obtained with the pure solution and the
pharmaceutical formulation as well as the statistical analyses
that provided the accuracy (the t-test) and the precision (the
F-test) (Miller and Miller, 1993). The accuracy and precision
of both methods (for the quantitation of CYC) were similar
because no important differences were found when comparing
the calculated and theoretical values of the t- and F-tests at the
95% conﬁdence level. The proposed methods for the spectro-
photometric quantitation of CYC can be applied at a wider
concentration range. However, for the proposed ion-pairs
Table 4 Determination of cyclizine hydrochloride in pharmaceutical preparation, applying the standard addition technique.
Reagent Cyclizine hydrochloride
Taken lg Added lg Found lg t-testa F-testa
Proposed method Reference methodb
I 20 15 35.30 35.20 1.86 1.84
50 69.71 70.31 2.08 1.96
70 90.64 90.72 0.14 1.46
II 20 15 34.87 1.68 2.76
50 70.68 1.49 1.97
70 89.76 0.34 2.47
III 20 15 34.81 34.94 1.92 3.48
50 69.37 70.20 1.28 2.84
70 90.31 89.89 2.34 1.76
IV 20 15 35.84 1.58 2.97
50 70.98 049 4.85
70 90.61 1.72 2.46
V 5 10 15.30 15.40 0.84 1.85
a Theoretical value for t- and F-test are 2.776 and 6.39, respectively, for four degree of freedom and 95% conﬁdence limit.
b El-Gindy et al. (2004).
Table 5 Determination of cyclizine hydrochloride in serum and urine by the proposed and reference method (El-Gindy et al., 2004).
Parameters Reagents
I II III IV V Reference method
Serum
Recoverya %± S.D. 99.94 ± 0.54 100.21 ± 0.44 99.64 ± 0.17 99.46 ± 0.37 99.97 ± 0.18 99.74 ± 0.55
Number of experiments 6 6 6 6 6 6
Variance 0.29 0.19 0.03 0.14 0.03 0.30
t-valuea 0.94 0.34 1.06 1.28 0.80 1.19
F-testa 2.14 3.46 1.84 3.68 2.94 3.54
Urine
Recoverya %± S.D. 100.54 ± 0.85 99.47 ± 0.82 100.84 ± 0.34 99.46 ± 0.43 100.84 ± 0.38 99.89 ± 0.37
Number of experiments 6 6 6 6 6 6
Variance 0.72 0.67 0.12 0.18 0.15 0.14
t-valueb 0.37 0.69 1.74 1.80 0.97 1.76
F-testb 3.48 2.54 3.69 3.97 2.86 3.75
a Average value of four determinations.
b Theoretical value for t- and F-test are 2.776 and 6.39, respectively, for four degree of freedom and 95% conﬁdence limit.
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6 min at ambient temperature (25 ± 1 C).
The proposed methods were successfully applied for the
determination of CYC in human serum and urine. The results
were compared with those obtained using the reference method
(El-Gindy et al., 2004) by applying Student’s t-test (to determine
the accuracy) and the F-test (to determine the precision). Table 5
lists the calculated t-values and F-values at the 95% conﬁdence
level. The results indicated that there is no difference in the accu-
racy and precision between the proposed methods and the ofﬁ-
cial method. The standard addition method was used for the
quantitation of CYC in human serum and urine (Table 5).4. Conclusions
The described methods for quantifying CYC using mono- and
bi-azo dyes were successfully applied. The methods have signif-
icant advantages compared with the reported methods listed in
Table 5. These advantages include high recovery, high sensitiv-ity, broad scope of applications, low relative standard devia-
tion, and simplicity of the methods. In addition, all of the
analytical reagents are cheap, have long shelf-lives and are
available in many analytical laboratories. Therefore, the meth-
ods should be practical and valuable for routine quantitation of
CYC in quality control laboratories. A comparative study for
reagents I–V was performed to determine the most sensitive re-
agent for the quantitation of CYC in its pure form and in a
pharmaceutical preparation. The results revealed that reagent
V had the highest molar absorptivity (1.3 · 104 L mol1 cm1)
and the lowest detection limit (0.40 lg).
These methods were used for the quantitation of CYC in
human serum and urine; the excellent recovery is a striking fea-
ture of the described methods.
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